1 min read
Add as a preferred source on Google

Belite Bio Shares Fall 13% as FDA Sets New Tinlarebant Action Date

The FDA set May 12, 2027, as the new action date for tinlarebant’s application for Stargardt disease type 1.

A sealed vial sits beside a softly lit laboratory window / TokenPost.ai (mono)
A sealed vial sits beside a softly lit laboratory window / TokenPost.ai (mono)

Belite Bio (BLTE) shares fell about 13% Friday, Nov. 20, 2026, after the U.S. Food and Drug Administration (FDA) moved the review deadline for the company’s tinlarebant application back by three months.

The agency set May 12, 2027, as the new target action date for the application for tinlarebant for Stargardt disease type 1.

Riza Dagoc

Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…